Ultragenyx Pharmaceutical
RARE
170 hedge funds and large institutions have $3.74B invested in Ultragenyx Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 43 reducing their positions, and 26 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 43
11% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $9.37M
0.31% more ownership
Funds ownership: 102.21% → 102.52% (+0.31%)
3% less funds holding
Funds holding: 176 → 170 (-6)
8% less capital invested
Capital invested by funds: $4.05B → $3.74B (-$306M)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$70.7M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$17.2M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$14M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.6M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$31.2M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$21.9M |
| 3 |
BlackRock
New York
|
-$21M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$17.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.4M |
RARE Hedge Fund Activity: Q2 2019 in Review
170 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2019, worth a combined $3.74B — down 7.6% from $4.05B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RARE and 22 opened new positions — a net loss of 4 holders — while 43 trimmed existing stakes and 75 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $70.7M. The largest seller was Citadel Advisors, cutting an estimated $31.2M.
- 170 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2019, down from 176 in Q1 2019.
- Funds reported $3.74B of Ultragenyx Pharmaceutical stock for Q2 2019, down 7.6% quarter-over-quarter.
- 22 funds opened new Ultragenyx Pharmaceutical positions in Q2 2019 and 26 closed out, a net change of -4 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2019 was T. Rowe Price Associates, an estimated $70.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2019 was Citadel Advisors, an estimated $31.2M sold.
Based on aggregated 13F filings for Q2 2019.